OIG to audit Pennsylvania's Medicaid MU program

Following up on its promise to conduct more Meaningful Use (MU) audits, the U.S. Department of Health and Human Services’ Office of Inspector General (OIG) plans to audit Pennsylvania's Medicaid program and its MU payments.

Based on discussions with other states that were audited, the OIG is likely to focus its audit on making sure hospital EHR Incentive Program payments were made correctly, and that the state Medicaid EHR Incentive Program payment calculations were accurate, according to an announcement posted on the website of the Hospital & Health System Association of Pennsylvania (HAP).

The Pennsylvania Department of Human Services (DHS), HAP also said, does not believe the OIG audit will involve actual hospital MU attestations, since hospitals attest directly to the Centers for Medicare & Medicaid Services (CMS), and CMS audits MU for hospitals.

The state's hospitals won't necessarily need to do anything but one has been contacted by OIG in connection with the state Medicaid EHR Incentive Program audit.

OIG conducted an MU audit of Massachusetts last year during which the agency found that the state made faulty payments to 19 hospitals, a $3.3 million error. The agency also conducted an audit of Louisiana and found incorrect payments totaling $1.4 million in overpayment.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.